Pharmaceutical Capsules

CIZUMAB 400 INJECTION contains Bevacizumab, which belongs to the group of medicines called Antineoplastic agents. It is used in adult patients with fluoropyrimidine (a chemotherapy medicine) to manage metastatic cancer in the large bowel (colon or rectum). It is also used with Paclitaxel or Capecitabine (chemotherapy medicine) to manage metastatic breast cancer in adult patients.

CIZUMAB 400 INJECTION is used with a chemotherapy regimen containing platinum to manage advanced non-small cell lung cancer without epidermal growth factor receptor (a mutated protein responsible for causing cancer in a cell) and with Erlotinib (a chemotherapy medicine) to manage metastatic non-small cell lung cancer with epidermal growth factor receptor (in cancer cells) in adult patients.

This medicine is indicated for use to manage metastatic kidney cancer along with interferon (chemotherapy medicine), which is also indicated for use with carboplatin, gemcitabine, and/or carboplatin and Paclitaxel (chemotherapy medicine) to manage recurrent advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in adult patients.

This medicine is also used to manage persistent, recurrent, or metastatic cervical cancer with or without Paclitaxel, Cisplatin, or Paclitaxel and Topotecan in adult patients. CIZUMAB 400 INJECTION is not recommended for use in patients allergic to Bevacizumab, Chinese hamster ovary (CHO) cell products, and/or other recombinant human or humanized antibodies. It is also not recommended for use in patients who have recently undergone major operations or surgery.

Before receiving CIZUMAB 400 INJECTION, inform your doctor if you are scheduled for an invasive dental treatment or surgery and/or suffer from conditions such as inflammation inside the abdomen, uncontrolled high blood pressure, dental problems, kidney problems, and liver problems (such as hepatic injury).

CIZUMAB 400 INJECTION is not recommended for use in pregnant women or in women planning for pregnancy since it may cause harm to the unborn baby. It is also not recommended for use by breast-feeding women since it may interfere with the growth and development of the baby.

CIZUMAB 400 INJECTION is not recommended for use in children and adolescents (aged below 18 years) since the safety and efficacy of the medicine are not established in this age group. It is advised to be used with caution in elderly patients (aged 65 years and older) after consulting the doctor.

The most common side effects of receiving CIZUMAB 400 INJECTION are constipation, loss of appetite, fever, eye problems (such as an increase in the production of tears), changes in speech or sense of taste, runny nose, and/or loss of body weight. Consult your doctor if any of these symptoms worsen.

To manage:

• Metastatic cancer in the large bowel (colon/rectum), breast, and kidney
• Advanced non-small cell lung cancer
• Recurrent advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer
• Persistent, recurrent, or metastatic cervical cancer

CIZUMAB 400 INJECTION works by reducing microvascular growth of tumour blood vessels which leads to reduced blood flow to the tumour cells resulting in its death thus treating the disease and preventing its spread to other parts of the body in affected individuals.

CIZUMAB 400 INJECTION will be given to you only by a doctor or a nurse into a vein as an intravenous infusion. Your doctor will determine the correct dose and duration for you based upon your age, body weight, and disease condition.